Beigene Ltd BGNE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/17/24 EDT
131.96UNCH (UNCH)
Volume
121,698
52 week range
131.28 - 270.57
Loading...
  • Open131.40
  • Day High136.00
  • Day Low131.40
  • Prev Close131.96
  • 52 Week High270.57
  • 52 Week High Date04/18/23
  • 52 Week Low131.28
  • 52 Week Low Date04/17/24

Key Stats

  • Market Cap13.789B
  • Shares Out104.49M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.67
  • YTD % Change-26.84

KEY STATS

  • Open131.40
  • Day High136.00
  • Day Low131.40
  • Prev Close131.96
  • 52 Week High270.57
  • 52 Week High Date04/18/23
  • 52 Week Low131.28
  • 52 Week Low Date04/17/24
  • Market Cap13.789B
  • Shares Out104.49M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.67
  • YTD % Change-26.84

RATIOS/PROFITABILITY

  • EPS (TTM)-8.51
  • P/E (TTM)-15.52
  • Fwd P/E (NTM)-14.67
  • EBITDA (TTM)-1.12B
  • ROE (TTM)-22.26%
  • Revenue (TTM)2.459B
  • Gross Margin (TTM)73.40%
  • Net Margin (TTM)-35.86%
  • Debt To Equity (MRQ)25.05%

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beigene Ltd

 

Profile

MORE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small...
John Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer, General Manager - China
Julia Wang
Chief Financial Officer
Address
94 Solaris Avenue,, Camana Bay
Grand Cayman, BEJ
KY1-1108
Cayman Islands